your market intelligence analyst
Search Results
22 results
Your search is now limited to «AstraZeneca» expert search.
Pharmafile 01/22/2020 05:32
AstraZeneca’s Tagrisso (osimertinib) has been knocked back for routine use on the NHS in England and Wales by the drug watchdog NICE in the treatment of previously treated, locally advanced or metastatic epidermal growth factor receptor (EGFR)-positive non-small-cell lung cancer (NSCLC). The decision is a reinforcement of one made in July last year after AstraZeneca appealed against the rejection.

Automotive Industries

Business Issues

Companies - Public

Companies - Venture Funded

Global Markets

Government Agencies

Information Technologies

Job Titles

Legal and Regulatory

Market Research Topics

Political Entities


Strategic Scenarios